| abstract |
Compounds, methods, and pharmaceutical compositions for reducing the amount or activity of LRRK2 RNA in cells or animals, and in certain cases for reducing the amount of LRRK2 protein in cells or animals are provided. The compounds, methods, and pharmaceutical compositions are useful for ameliorating at least five signs or characteristics of neurodegenerative diseases. Such signs and features include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include Parkinson's disease. |